Table 1.
Patient characteristics of three completed clinical trials in head and neck squamous cell carcinoma (HNSCC) patients; HN0501 (phase II docetaxel and bortezomib as first-line therapy for recurrent/metastatic HNSCC), E5397 (phase III cisplatin with/without cetuximab as first-line therapy for recurrent/metastatic HNSCC), and HN0582 (phase II pemetrexed and oxaliplatin induction followed by chemoradiation in newly diagnosed HNSCC)
| HN0501 |
E5397 |
HN0582 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TG/GG (N = 8) |
TT (N = 11) |
TG/GG (N = 12) |
TT (N = 42) |
TG/GG (N = 10) |
TT (N = 12) |
|||||||
| n | % | n | % | n | % | n | % | n | % | n | % | |
| Age (median, range) | 54 (35–62) | 54 (41–76) | 56 (42–83) | 58 (36–85) | 56 (36–66) | 57 (41–74) | ||||||
| Sex | ||||||||||||
| Male | 7 | 88 | 6 | 75 | 11 | 92 | 32 | 76 | 8 | 80 | 11 | 92 |
| Female | 1 | 12 | 2 | 25 | 1 | 8 | 10 | 24 | 2 | 20 | 1 | 8 |
| Unknown | 0 | – | 3 | – | 0 | – | 0 | – | 0 | – | 0 | – |
| Race | ||||||||||||
| White | 7 | 88 | 7 | 64 | 11 | 92 | 37 | 88 | 10 | 100 | 11 | 92 |
| Black | 1 | 12 | 1 | 9 | 1 | 8 | 4 | 10 | 0 | 0 | 1 | 8 |
| Others/unknown | 0 | 0 | 3 | 27 | 0 | 0 | 1 | 2 | 0 | – | 0 | – |
| Path differentiation | ||||||||||||
| Well differentiated | 0 | 0 | 0 | 0 | 2 | 20 | 5 | 12 | 0 | 0 | 0 | 0 |
| Moderately differentiated | 3 | 43 | 5 | 83 | 4 | 40 | 20 | 49 | 5 | 56 | 9 | 82 |
| Poorly differentiated | 4 | 57 | 1 | 17 | 4 | 40 | 16 | 39 | 4 | 44 | 2 | 18 |
| Unknown | 1 | – | 5 | – | 2 | – | 1 | – | 1 | – | 1 | – |
| Disease subsites | ||||||||||||
| Oral cavity | 2 | 25 | 3 | 30 | 1 | 8 | 10 | 24 | 0 | 0 | 1 | 8 |
| Oropharynx | 4 | 50 | 7 | 70 | 4 | 33 | 13 | 31 | 7 | 70 | 8 | 60 |
| Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 10 | 0 | 0 | 1 | 8 |
| Larynx | 1 | 12 | 0 | 0 | 3 | 25 | 12 | 29 | 2 | 20 | 1 | 8 |
| Others | 1 | 12 | 0 | 0 | 4 | 33 | 3 | 7 | 1 | 10 | 1 | 8 |
| Unknown | 0 | – | 1 | – | 0 | – | 0 | – | 0 | – | 0 | – |